{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:16:20Z","timestamp":1775063780592,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1053\/j.seminhematol.2024.10.009","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T23:51:52Z","timestamp":1730937112000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A line in shifting sand: Can we define and target TP53 mutated MDS?"],"prefix":"10.1053","volume":"61","author":[{"given":"Sarah","family":"Skuli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2024.10.009_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2023.101055","article-title":"TP53 in AML and MDS: the new (old) kid on the block","volume":"60","author":"Marks","year":"2023","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0004","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0005","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/EDBK_432650","article-title":"TP53 mutations in acute leukemias and myelodysplastic syndromes: insights and treatment updates","volume":"44","author":"Santini","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0007","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/gcc.21993","article-title":"Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion","volume":"51","author":"Sebaa","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0008","doi-asserted-by":"crossref","unstructured":"S. Ogawa, Review Series MYELODYSPLASTIC SYNDROMES Genetics of MDS, 2019. http:\/\/ashpublications.org\/blood\/article-pdf\/133\/10\/1049\/1556859\/blood844621.pdf. Access date: 07\/25\/2024.","DOI":"10.1182\/blood-2018-10-844621"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0010","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/10428194.2016.1266625","article-title":"The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications","volume":"58","author":"Zhang","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0011","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0012","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0013","doi-asserted-by":"crossref","unstructured":"T. Grob, B. Biemond, Molecular characterization of mutant tp53 acute myeloid leukemia and high-risk myelodysplastic syndrome, (n.d.), 2347\u201354. https:\/\/doi.org\/10.1182\/blood.2021014472\/1867766\/blood.2021014472.pdf.","DOI":"10.1182\/blood.2021014472"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0014","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0015","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0016","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1182\/blood.V88.11.4296.bloodjournal88114296","article-title":"Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype","volume":"88","author":"Ben-Yehuda","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0017","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ejh.13207","article-title":"Molecular pathogenesis of myelodysplastic syndromes with deletion 5q","volume":"102","author":"hoon Lee","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21103432","article-title":"TP53 in myelodysplastic syndromes: recent biological and clinical findings","volume":"21","author":"Cumbo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0019","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0020","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0021","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41388-021-02141-5","article-title":"p53 partial loss-of-function mutations sensitize to chemotherapy","volume":"41","author":"Klimovich","year":"2022","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0022","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0023","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal TP53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0024","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2023-179171","article-title":"TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion","volume":"142","author":"Montoro","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0026","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0027","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/ejh.13483","article-title":"The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis","volume":"105","author":"Deng","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0029","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.3324\/haematol.2016.143214","article-title":"Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"101","author":"McGraw","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0030","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3324\/haematol.2018.205302","article-title":"TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies","volume":"104","author":"Ruzinova","year":"2019","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0031","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/his.14726","article-title":"Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia","volume":"81","author":"Fitzpatrick","year":"2022","journal-title":"Histopathology"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0032","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3324\/haematol.2021.280487","article-title":"Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases","volume":"107","author":"Fang","year":"2022","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0033","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5468\/ogs.22102","article-title":"Clinical outcomes of immunohistochemistry of the p53 staining pattern in high-grade serous ovarian carcinoma","volume":"65","author":"Orachum","year":"2022","journal-title":"Obstet Gynecol Sci"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0034","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41379-022-01062-2","article-title":"p53 null phenotype is a \u201cpositive result\u201d in urothelial carcinoma in situ","volume":"35","author":"Sangoi","year":"2022","journal-title":"Modern Pathology"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0035","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2016.74","article-title":"High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS\/AML cohort","volume":"30","author":"Goel","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0036","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.10.009_bib0037","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1080\/10428194.2024.2332505","article-title":"Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach","volume":"65","author":"Matthews","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.771614","article-title":"BMT for Myelodysplastic Syndrome: When and Where and How","volume":"11","author":"Jain","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0039","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2016.03.029","article-title":"Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome","volume":"22","author":"Festuccia","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0040","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.18632\/oncotarget.12511","article-title":"Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts","volume":"8","author":"Yahng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0041","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2016.05.026","volume":"22","author":"Potter","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0042","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2016.266","article-title":"Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: A retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT","volume":"52","author":"Robin","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0043","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced mds according to donor availability (vidazaallo study)","volume":"39","author":"Kroger","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0044","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0045","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14455","article-title":"TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes","volume":"176","author":"Chang","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0046","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0047","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0049","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/hemato3040050","article-title":"TP53 Mutant Acute Myeloid Leukemia: The Immune and Metabolic Perspective","volume":"3","author":"Zingarelli","year":"2022","journal-title":"Hemato"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.1033534","article-title":"Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia","volume":"12","author":"Ambinder","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bneo.2024.100004","article-title":"Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression","volume":"1","author":"Jambhekar","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0052","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0053","first-page":"1","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0054","doi-asserted-by":"crossref","unstructured":"V. Mohanty, N. Baran, Y. Huang, et al. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML, (n.d.). https:\/\/www.biorxiv.org\/content\/10.1101\/2024.01.27.577579v1. Access date: 07\/25\/2024.","DOI":"10.1101\/2024.01.27.577579"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2023-185059","article-title":"The Mevalonate pathway is a therapeutic target in TP53 mutant acute myeloid leukemia","volume":"142","author":"Skuli","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0056","first-page":"2022","article-title":"Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response","volume":"142","author":"Skuli","year":"2023","journal-title":"SJS"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0057","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","article-title":"Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells","volume":"16","author":"Mueller","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0058","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2023-186454","article-title":"Age-specific induction of mutant p53 drives clonal hematopoiesis in adult mice leading to acute myeloid leukemia","volume":"142","author":"Pourebrahim","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0059","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0060","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0061","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241257904","article-title":"Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine","volume":"15","author":"Zeidan","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0062","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","article-title":"Release of IFNg by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells","volume":"28","author":"Corradi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0063","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00277-022-04766-2","article-title":"Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations","volume":"101","author":"Dutta","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0064","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00277-024-05679-y","article-title":"Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia","volume":"103","author":"Chen","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0065","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0066","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00969-6","article-title":"Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms","volume":"14","author":"Gou","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0068","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.3324\/haematol.2022.282349","article-title":"Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation","volume":"108","author":"Muto","year":"2023","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embr.202154262","article-title":"NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss","volume":"23","author":"Morganti","year":"2022","journal-title":"EMBO Rep"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0070","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/bloodadvances.2022008926","article-title":"Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation","volume":"8","author":"Fuchs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0071","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/onc.2012.139","article-title":"Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"Wei","year":"2013","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0072","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0073","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1182\/blood-2023-191061","article-title":"NAMPT haploinsufficiency is a therapeutic vulnerability in high-risk myeloid malignancies","volume":"142","author":"Senagolage","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0074","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/bloodadvances.2023010435","article-title":"Monosomy 7\/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia","volume":"8","author":"Eldfors","year":"2024","journal-title":"Blood Adv"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.10.009_bib0075","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0076","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for tp53 -mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0077","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0078","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood-2022-169765","article-title":"XPO1 overexpression is a mechanism of resistance to eprenetapopt and 5-azacitidine therapy that can be therapeutically exploited for the treatment of TP53 mutated myeloid malignancies","volume":"140","author":"Kruer","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14235906","article-title":"Targeting menin and CD47 to address unmet needs in acute myeloid leukemia","volume":"14","author":"Matthews","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0080","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0081","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0082","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood-2023-188285","article-title":"Targeting mitochondrial calcium uptake to eradicate venetoclax-resistant acute myeloid leukemia stem cells","volume":"142","author":"Sheth","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14143557","article-title":"NF-\u03baB: a druggable target in acute myeloid leukemia","volume":"14","author":"Di Francesco","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2024.10.009_bib0084","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3249.BCDSYMP24-P34","article-title":"Abstract P34: Bayesian networks modeling identifies a reliance of TP53 mutant AML on NF kappa B signaling","volume":"5","author":"Chang","year":"2024","journal-title":"Blood Cancer Discov"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:53:19Z","timestamp":1734025999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0037196324001264"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.009","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A line in shifting sand: Can we define and target TP53 mutated MDS?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}